Perfluorohexyloctane (NOV03) for the Treatment of Signs and Symptoms of Dry Eye Disease (DED)

Summary

This study will evaluate the efficacy, safety and tolerability of perfluorohexyloctane (NOV03) at two different dosing regimens compared to saline solution in subjects with Dry Eye Disease (DED).

Timeline

Start

2018-01-03

Primary completion

2018-05-18

Completion

2018-07-27

Outcome

Met primary endpoint

paper The study met its primary endpoint, change from baseline of tCFS over control, for both dosing regimens QID and BID PMID 33369937 ↗

release “The SEECASE trial met its prespecified primary endpoint for both treatment schedules at 8 weeks” novaliq.com ↗

Publications

• Results Tauber J, Wirta DL, Sall K, Majmudar PA, Willen D, Krosser S; SEECASE study group. A Randomized Clinical Study (SEECASE) to Assess Efficacy, Safety, and Tolerability of NOV03 for Treatment of Dry Eye Disease. Cornea. 2021 Sep 1;40(9):1132-1140. doi: 10.1097/ICO.0000000000002622.

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Perfluorohexyloctane	Unknown	—	—

Indications